Laboratory of Gene Therapy, Biocad Biotechnology Company, Saint-Petersburg, Strelnya 198515, Russia.
Federal Scientific Clinical Center for Resuscitation and Rehabilitation, Moscow 109240, Russia.
Biomolecules. 2019 Aug 18;9(8):377. doi: 10.3390/biom9080377.
Atherosclerosis-related cardiovascular diseases remain the leading cause of morbidity and mortality, and the search for novel diagnostic and therapeutic methods is ongoing. Mitochondrial DNA (mtDNA) mutations associated with atherosclerosis represent one of the less explored aspects of the disease pathogenesis that may bring some interesting opportunities for establishing novel molecular markers and, possibly, new points of therapeutic intervention. Recent studies have identified a number of mtDNA mutations, for which the heteroplasmy level was positively or negatively associated with atherosclerosis, including the disease at its early, subclinical stages. In this review, we summarize the results of these studies, providing a list of human mtDNA mutations potentially involved in atherosclerosis. The molecular mechanisms underlying such involvement remain to be elucidated, although it is likely that some of them may be responsible for the increased oxidative stress, which plays an important role in atherosclerosis.
动脉粥样硬化相关心血管疾病仍然是发病率和死亡率的主要原因,因此正在寻找新的诊断和治疗方法。与动脉粥样硬化相关的线粒体 DNA(mtDNA)突变是疾病发病机制中研究较少的方面之一,它可能为建立新的分子标志物并可能为新的治疗干预点带来一些有趣的机会。最近的研究已经确定了一些 mtDNA 突变,其异质性水平与动脉粥样硬化呈正相关或负相关,包括疾病的早期亚临床阶段。在这篇综述中,我们总结了这些研究的结果,提供了一份可能与动脉粥样硬化有关的人类 mtDNA 突变列表。虽然一些 mtDNA 突变可能与氧化应激增加有关,而氧化应激在动脉粥样硬化中起着重要作用,但这些 mtDNA 突变的潜在分子机制仍有待阐明。